Eltrombopag

Generic Name: Eltrombopag

Brand Names: Promacta, Revolade

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₂N_₄O_₄

CAS Number: 496775-61-2

Unique Ingredient Identifier: S56D65XJ9G

Background: Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication: Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions: Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia

Associated Therapies: First-line Therapy

Clinical Trials

Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Conditions: Poor Graft Function

Interventions: Drug: Eltrombopag

First Posted Date: 2018-02-19

Last Posted Date: 2018-02-19

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 20

Registration Number: NCT03437603

Locations: 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

Phase 3

Conditions: Acquired Aplastic Anemia

Interventions: Drug: Eltrombopag
Drug: IST (ATG + CsA)

First Posted Date: 2018-01-29

Last Posted Date: 2021-03-15

Lead Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Target Recruit Count: 100

Registration Number: NCT03413306

Locations: 🇷🇺
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.

Not Applicable

Completed

Conditions: Idiopathic Thrombocytopenic Purpura

Interventions: Drug: conventional
Drug: Eltrombopag

First Posted Date: 2018-01-26

Last Posted Date: 2021-10-28

Lead Sponsor: Nayera Hazaa Elsherif

Target Recruit Count: 36

Registration Number: NCT03412188

Locations: 🇪🇬
Ainshams University , Faculty of medicine , Pediatric Hematology&Oncology unit, children hospital., Cairo, Egypt

Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia

Phase 4

Completed

Conditions: Eltrombopag

Interventions: Drug: Eltrombopag

First Posted Date: 2017-08-09

Last Posted Date: 2022-01-18

Lead Sponsor: Assiut University

Target Recruit Count: 20

Registration Number: NCT03243656

Locations: 🇪🇬
Facility of medicine, Assiut, Egypt

Eltrombopag for People With Fanconi Anemia

Phase 2

Recruiting

Conditions: Fanconi Anemia

Interventions: Drug: Eltrombopag

First Posted Date: 2017-07-02

Last Posted Date: 2024-11-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 35

Registration Number: NCT03206086

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Phase 2

Active, not recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag
Drug: hATG
Drug: CsA

First Posted Date: 2017-01-19

Last Posted Date: 2024-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT03025698

Locations: 🇺🇸
Aflac Cancerand Blood Disorders Ctr, Atlanta, Georgia, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago SC, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Foundation Cleveland Clinic 5, Cleveland, Ohio, United States

and more 10 locations

Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

Phase 2

Completed

Conditions: Severe Aplastic Anemia

Interventions: Drug: eltrombopag
Drug: Cyclosporine

First Posted Date: 2016-12-20

Last Posted Date: 2023-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT02998645

Locations: 🇹🇷
Novartis Investigative Site, Samsun, Turkey

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Phase 3

Conditions: Immune Thrombocytopenic Purpura (ITP)

Interventions: Drug: Eltrombopag

First Posted Date: 2016-08-24

Last Posted Date: 2016-08-24

Lead Sponsor: National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

Target Recruit Count: 75

Registration Number: NCT02877212

Locations: 🇵🇰
Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Punjab, Pakistan

Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia

Phase 2

Conditions: Immune Thrombocytopenia

Interventions: Drug: Rituximab
Drug: Eltrombopag
Drug: Dexamethasone

First Posted Date: 2016-07-15

Last Posted Date: 2016-07-15

Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez

Target Recruit Count: 15

Registration Number: NCT02834286

Locations: 🇲🇽
Servicio de Hematología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)

Phase 2

Conditions: Anemia, Aplastic

Interventions: Drug: Placebo (for Eltrombopag)
Drug: Eltrombopag

First Posted Date: 2016-05-16

Last Posted Date: 2018-02-05

Lead Sponsor: B. Höchsmann

Target Recruit Count: 116

Registration Number: NCT02773225

Locations: 🇩🇪
University Hospital Ulm, Ulm, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy